See more : Draganfly Inc. (DPRO) Income Statement Analysis – Financial Results
Complete financial analysis of Yield10 Bioscience, Inc. (YTEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Yield10 Bioscience, Inc., a leading company in the Agricultural Inputs industry within the Basic Materials sector.
You may be interested
- Guangdong Jiaying Pharmaceutical Co., Ltd (002198.SZ) Income Statement Analysis – Financial Results
- Golden Apple Oil & Gas Inc. (GAPJ) Income Statement Analysis – Financial Results
- Seres Group Co.,Ltd. (601127.SS) Income Statement Analysis – Financial Results
- Collective Mining Ltd. (CNLMF) Income Statement Analysis – Financial Results
- Simon Property Group Acquisition Holdings, Inc. (SPGS-UN) Income Statement Analysis – Financial Results
Yield10 Bioscience, Inc. (YTEN)
About Yield10 Bioscience, Inc.
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing technologies to enable step-change increases in crop yield in the United States and Canada. The company, through its Trait Factory, a trait gene discovery platform develops enhanced oilseed Camelina sativa for the production of proprietary seed products; and discovers high value genetic traits for the agriculture and food industries. Yield10 Bioscience, Inc. has license agreements with GDM Seeds; J. R. Simplot; Forage Genetics International, LLC; and Bayer AG. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was incorporate in 1992 and is headquartered in Woburn, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 60.00K | 450.00K | 614.00K | 799.00K | 806.00K | 556.00K | 944.00K | 1.16M | 2.59M | 2.80M | 5.39M | 42.32M | 1.43M | 448.00K | 1.43M | 1.56M | 1.68M | 4.59M | 2.78M | 3.68M | 2.38M | 1.99M |
| Cost of Revenue | 290.00K | 656.00K | 578.00K | 5.22M | 4.85M | 4.78M | 4.60M | 5.67M | 660.00K | 1.48M | 3.03M | 1.43M | 24.45M | 23.67M | 24.47M | 24.67M | 19.90M | 11.24M | 5.98M | 5.43M | 0.00 | 0.00 |
| Gross Profit | -230.00K | -206.00K | 36.00K | -4.42M | -4.04M | -4.23M | -3.65M | -4.51M | 1.93M | 1.32M | 2.37M | 40.89M | -23.02M | -23.23M | -23.05M | -23.11M | -18.22M | -6.65M | -3.20M | -1.75M | 2.38M | 1.99M |
| Gross Profit Ratio | -383.33% | -45.78% | 5.86% | -553.32% | -501.49% | -760.25% | -386.97% | -389.21% | 74.56% | 47.07% | 43.90% | 96.63% | -1,615.44% | -5,184.15% | -1,617.26% | -1,486.30% | -1,082.47% | -144.77% | -115.04% | -47.53% | 100.00% | 100.00% |
| Research & Development | 8.32M | 7.75M | 6.20M | 5.36M | 4.85M | 4.78M | 4.60M | 5.67M | 16.57M | 17.34M | 19.13M | 23.18M | 0.00 | 0.00 | 0.00 | 24.67M | 19.90M | 11.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 6.15M | 6.15M | 6.11M | 5.05M | 4.55M | 5.09M | 5.63M | 5.74M | 9.11M | 10.81M | 13.74M | 14.11M | 15.84M | 15.71M | 15.68M | 15.78M | 15.60M | 10.88M | 3.83M | 3.25M | 0.00 | 2.64M |
| Other Expenses | 0.00 | 41.00K | -3.00K | 83.00K | 21.00K | 134.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 25.68M | 28.15M | 32.87M | 37.29M | 15.84M | 15.71M | 15.68M | 40.45M | 35.50M | 22.11M | 3.83M | 3.25M | 0.00 | 7.05M |
| Cost & Expenses | 14.48M | 13.90M | 12.31M | 10.41M | 9.40M | 9.88M | 10.23M | 11.41M | 26.34M | 29.63M | 35.90M | 38.71M | 40.29M | 39.39M | 40.15M | 40.45M | 35.50M | 22.11M | 9.81M | 8.68M | 0.00 | 7.05M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 96.00K | 158.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 76.00K | 0.00 | 0.00 | 0.00 | 5.94M | 1.47M | 109.36K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 13.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -80.00K | 0.00 | 772.00K | 2.89M | 0.00 | 5.00K | 10.14K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 290.00K | 656.00K | 578.00K | 611.00K | 1.83M | 784.00K | 206.00K | 177.00K | 265.00K | 507.00K | 928.00K | 1.30M | 1.51M | 1.65M | 2.73M | 3.73M | 1.45M | 964.00K | 314.57K | 265.25K | 0.00 | 0.00 |
| EBITDA | -14.13M | -13.19M | -11.47M | -9.43M | -8.39M | -9.12M | -9.08M | -10.07M | -12.35M | -26.32M | -27.61M | 4.90M | -37.35M | -37.29M | -36.00M | -35.16M | -32.37M | -16.56M | -6.71M | -4.73M | 2.38M | -5.06M |
| EBITDA Ratio | -23,545.00% | -2,930.67% | -1,982.41% | -1,101.75% | -609.93% | -1,640.83% | -949.58% | -836.50% | -907.48% | -942.25% | -547.26% | 11.58% | -2,621.33% | -8,324.11% | -2,525.96% | -2,261.16% | -1,923.05% | -360.78% | -216.11% | -128.73% | 100.00% | -254.60% |
| Operating Income | -14.42M | -13.45M | -11.69M | -9.61M | -8.60M | -9.32M | -9.28M | -10.25M | -23.74M | -26.83M | -30.50M | 3.60M | -38.86M | -38.94M | -38.73M | -38.89M | -33.82M | -17.52M | -7.02M | -5.00M | 2.38M | -5.06M |
| Operating Income Ratio | -24,028.33% | -2,989.11% | -1,904.23% | -1,202.63% | -1,066.50% | -1,676.08% | -983.37% | -884.21% | -915.30% | -958.18% | -565.48% | 8.51% | -2,727.09% | -8,691.74% | -2,717.82% | -2,501.09% | -2,009.27% | -381.79% | -252.59% | -135.94% | 100.00% | -254.60% |
| Total Other Income/Expenses | -38.00K | 41.00K | 697.00K | -541.00K | -4.61M | 134.00K | -113.00K | -38.00K | 29.00K | 61.00K | -4.00K | 27.00K | 76.00K | 136.00K | 0.00 | 0.00 | 5.94M | 1.46M | -699.64K | 0.00 | -2.38M | 5.06M |
| Income Before Tax | -14.46M | -13.41M | -11.00M | -10.15M | -13.21M | -9.19M | -9.40M | -10.29M | -23.68M | -26.77M | -30.51M | 3.63M | -38.79M | -38.80M | 0.00 | 0.00 | -27.88M | -16.06M | -7.72M | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -24,091.67% | -2,980.00% | -1,790.72% | -1,270.34% | -1,638.96% | -1,651.98% | -995.34% | -887.49% | -912.91% | -956.00% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | 0.00% | 0.00% | -1,656.27% | -349.93% | -277.76% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 156.00K | 36.00K | 56.00K | -254.00K | 104.00K | 113.00K | -1.10M | -62.00K | 2.71M | 4.00K | 0.00 | 0.00 | 0.00 | -772.00K | -2.89M | 0.00 | 0.00 | 600.79K | 54.31K | 6.64M | 5.19M |
| Net Income | -14.46M | -13.57M | -11.03M | -10.21M | -12.96M | -9.19M | -9.40M | -7.60M | -23.68M | -29.53M | -30.51M | 3.63M | -38.79M | -38.80M | -37.96M | -36.01M | -27.88M | -16.06M | -7.63M | -5.05M | -6.64M | -5.19M |
| Net Income Ratio | -24,091.67% | -3,014.67% | -1,796.58% | -1,277.35% | -1,607.44% | -1,651.98% | -995.34% | -656.08% | -912.91% | -1,054.79% | -565.55% | 8.58% | -2,721.75% | -8,661.38% | -2,663.65% | -2,315.43% | -1,656.27% | -349.93% | -274.20% | -137.42% | -278.62% | -260.83% |
| EPS | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -149.23K | -79.89K | -158.62K | -100.88K |
| EPS Diluted | -43.66 | -66.25 | -55.95 | -103.21 | -851.98 | -887.78 | -2.77K | -2.65K | -9.18K | -27.97K | -51.50K | 277.48 | -72.21K | -84.34K | -94.26K | -91.74K | -73.75K | -172.10K | -121.96K | -79.89K | -158.62K | -100.88K |
| Weighted Avg Shares Out | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 588.00 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 51.10 | 63.27 | 41.86 | 51.43 |
| Weighted Avg Shares Out (Dil) | 331.10K | 204.77K | 197.16K | 98.89K | 15.21K | 10.35K | 3.39K | 2.87K | 2.58K | 1.06K | 592.33 | 589.07 | 537.10 | 460.06 | 402.69 | 392.46 | 377.99 | 93.33 | 62.52 | 63.27 | 41.86 | 51.43 |
Yield10 Bioscience to Present at the MicroCap Rodeo Presents: Windy City Roundup 2022 on October 12
WOBURN, MA / ACCESSWIRE / October 6, 2022 / Yield10 Bioscience, Inc. (NASDAQ:YTEN) ("Yield10" or the "Company"), an agricultural bioscience company, has been invited to present at the MicroCap Rodeo presents: The Windy City Roundup 2022 investor conference, which is...
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advancements in Producing PHA Bioplastic in Camelina at the ISBP 2022 Conference
WOBURN, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the International Symposium on Biopolymers (“ISBP”) 2022...
Yield10 Bioscience to Present at the 24th Annual H.C. Wainwright Global Investment Conference
WOBURN, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that President and CEO Oliver Peoples, Ph.D. will present a corporate overview at the 24th Annual H.C. Wainwright...
Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q2 2022 Results - Earnings Call Transcript
Yield10 Bioscience, Inc. (NASDAQ:YTEN ) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Lynne Brum - VP, Planning & Corporate Communications & Secretary Oliver Peoples - Co-Founder, President, CEO & Director Kristi Snell - VP,...
Metabolix, Inc. (YTEN) Reports Q2 Loss, Misses Revenue Estimates
Metabolix, Inc. (YTEN) delivered earnings and revenue surprises of -1.45% and 37.20%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Yield10 Bioscience to Announce Second Quarter 2022 Financial Results and Host a Conference Call on Wednesday, August 10, 2022
WOBURN, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that the Company will report its second quarter 2022 financial results and provide a corporate update on Wednesday,...
Yield10 Bioscience Chief Science Officer Dr. Kristi Snell to Present on Advancements in Producing PHA Bioplastic in Camelina at the CROPS 2022: Improving Agriculture Through Genomics Conference
WOBURN, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that its Chief Science Officer Dr. Kristi Snell will present during the CROPS 2022: Improving Agriculture Through Genomics...
5 Stocks to Watch on Robust Agriculture Operations Industry Trends
The Agriculture - Operations industry shows potential on solid demand trends, organic product growth and innovation ability. Players like ADM, CTVA, YTEN, AGRO and CVGW have placed themselves well.
Yield10 Bioscience to Present at the H.C. Wainwright Global Hybrid Investment Conference
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq: YTEN) (“Yield10” or the “Company”), an agricultural bioscience company, today announced that President and CEO Oliver Peoples, Ph.D. will present a corporate overview at the H.C. Wainwright Global Hybrid...
Yield10 Bioscience, Inc. (YTEN) CEO Oliver Peoples on Q1 2022 Results - Earnings Call Transcript
Yield10 Bioscience, Inc. (NASDAQ:YTEN ) Q1 2022 Results Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Lynne Brum - Vice President, Planning and Corporate Communications Oliver Peoples - President and Chief Executive Officer Kristi Snell - Vice...
Source: https://incomestatements.info
Category: Stock Reports